6 ms·
Right, but as the comment above was pointing out, there are many other factors. Pfizer/Moderena both did their trial from July-November, whereas J&J did their
by ehsankia 6y ago
Right, but as the comment above was pointing out, there are many other factors.
Pfizer/Moderena both did their trial from July-November, whereas J&J did their phase 3 from Sept-January. Looking at the COVID case graph [0], you can see J&J was tested at the peak. Not only that, J&J was party tested in the UK and South Africa, when the two new variants were starting to take over.
[0] https://media.npr.org/assets/img/2021/02/15/seamus-coronavirus-d3-us-map-20200312_wide-fa4e52108f37e9bc8a97850e22ec10063bd4fa22.png https://media.npr.org/assets/img/2021/02/15/seamus-coronavir...
- bgentry 6y agoJust this week we also saw data from Pfizer & Moderna mRNA vaccine rollouts to frontline healthcare workers in December (at a time of peak infection and emerging variants) that touted 80% effectiveness after a single dose, 90% after two doses. I'm struggling to find a reason not to interpret that as further evidence that the mRNA vaccines are in fact more effective than the J&J shot. Medical workers take precautions better than the general public, maybe? But they're also far more exposed.
- ehsankia 6y ago80% with one dose seems right in line with 75% with one dose of J&J (in the US). For what it's worth, J&J is also now doing a phase trial of two doses, and I expect that to be around 90% too. So yes, once you take into account the +/- 5% error, they seem to be pretty much equal.